HUP9902808A2 - 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása - Google Patents

5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása

Info

Publication number
HUP9902808A2
HUP9902808A2 HU9902808A HUP9902808A HUP9902808A2 HU P9902808 A2 HUP9902808 A2 HU P9902808A2 HU 9902808 A HU9902808 A HU 9902808A HU P9902808 A HUP9902808 A HU P9902808A HU P9902808 A2 HUP9902808 A2 HU P9902808A2
Authority
HU
Hungary
Prior art keywords
benzisothiazol
indol
piperazinyl
dihydro
chloro
Prior art date
Application number
HU9902808A
Other languages
English (en)
Inventor
Frank R. Busch
Carol A. Rose
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP9902808A2 publication Critical patent/HUP9902808A2/hu
Publication of HUP9902808A3 publication Critical patent/HUP9902808A3/hu
Publication of HU229057B1 publication Critical patent/HU229057B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgya 5-(2-(4-(1,2-benzizőtiazől-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidrő-2H-indől-2-őn-meziláttrihidrát sói, amezilát-trihidrát-sókat tartalmazó gyógyászati készítmények és eljárása vegyületek alkalmazására pszichőtikűs rendellenességek kezelésénél. ŕ
HU9902808A 1996-05-07 1997-03-26 Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist HU229057B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07
PCT/IB1997/000306 WO1997042190A1 (en) 1996-05-07 1997-03-26 Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Publications (3)

Publication Number Publication Date
HUP9902808A2 true HUP9902808A2 (hu) 2000-03-28
HUP9902808A3 HUP9902808A3 (en) 2000-04-28
HU229057B1 HU229057B1 (en) 2013-07-29

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902808A HU229057B1 (en) 1996-05-07 1997-03-26 Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist

Country Status (46)

Country Link
US (1) US6110918A (hu)
EP (1) EP0904273B1 (hu)
JP (1) JP3102896B2 (hu)
KR (1) KR100333214B1 (hu)
CN (1) CN1092658C (hu)
AP (1) AP838A (hu)
AR (1) AR007003A1 (hu)
AT (1) ATE236902T1 (hu)
AU (1) AU730856C (hu)
BG (1) BG63601B1 (hu)
BR (1) BR9708932A (hu)
CA (1) CA2252895C (hu)
CO (1) CO4940465A1 (hu)
CZ (1) CZ289216B6 (hu)
DE (1) DE69720719T2 (hu)
DK (1) DK0904273T3 (hu)
DZ (1) DZ2221A1 (hu)
EA (1) EA001180B1 (hu)
EG (1) EG24401A (hu)
ES (1) ES2192264T3 (hu)
GT (1) GT199700042A (hu)
HK (1) HK1017893A1 (hu)
HN (1) HN1997000040A (hu)
HR (1) HRP970235B1 (hu)
HU (1) HU229057B1 (hu)
ID (1) ID17504A (hu)
IL (1) IL126590A (hu)
IS (1) IS2301B (hu)
MA (1) MA26427A1 (hu)
ME (1) ME00901B (hu)
MY (1) MY128051A (hu)
NO (1) NO312513B1 (hu)
NZ (2) NZ508303A (hu)
OA (1) OA10908A (hu)
PL (1) PL188164B1 (hu)
PT (1) PT904273E (hu)
SI (1) SI0904273T1 (hu)
SK (1) SK282674B6 (hu)
TN (1) TNSN97073A1 (hu)
TR (1) TR199802241T2 (hu)
TW (1) TW427989B (hu)
UA (1) UA47467C2 (hu)
UY (1) UY24543A1 (hu)
WO (1) WO1997042190A1 (hu)
YU (1) YU49398B (hu)
ZA (1) ZA973875B (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
EP0985414B1 (en) * 1998-05-26 2003-08-27 Pfizer Products Inc. Medicament for the treatment of glaucoma and ischemic retinopathy
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP1712222A3 (en) 1999-12-23 2012-06-20 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
NZ551012A (en) * 2000-06-02 2008-04-30 Pfizer Prod Inc Use of S-methyl-dihydro-ziprasidone administered via either the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal or topical routes in doses ranging from 0.5 to 500 mg per day
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
AU2003300814A1 (en) 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
EP1633360A1 (en) * 2003-05-16 2006-03-15 Pfizer Products Incorporated Treatment of psychotic and depressive disorders
EP1633361A1 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Anxiety treatments with ziprasidone
CA2625837A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
CA2528100A1 (en) * 2003-06-03 2005-04-21 Teva Pharmaceutical Industries Ltd Polymorphic forms of ziprasidone hcl and processes for their preparation
EP1663166A2 (en) * 2003-09-02 2006-06-07 Imran Ahmed Sustained release dosage forms of ziprasidone
US7667037B2 (en) * 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
CN1934108A (zh) * 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICULAR COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
AU730856B2 (en) 2001-03-15
HU229057B1 (en) 2013-07-29
EG24401A (en) 2009-04-29
CN1092658C (zh) 2002-10-16
IS2301B (is) 2007-10-15
GT199700042A (es) 1998-10-02
EP0904273A1 (en) 1999-03-31
HRP970235A2 (en) 1998-06-30
NZ332219A (en) 2005-02-25
UA47467C2 (uk) 2002-07-15
IL126590A0 (en) 1999-08-17
EA199800909A1 (ru) 1999-04-29
AP9700978A0 (en) 1997-07-31
MA26427A1 (fr) 2004-12-20
TW427989B (en) 2001-04-01
SK150598A3 (en) 2000-03-13
HRP970235B1 (en) 2002-08-31
CZ349498A3 (cs) 1999-09-15
HUP9902808A3 (en) 2000-04-28
WO1997042190A1 (en) 1997-11-13
NO985193L (no) 1998-11-06
PL329880A1 (en) 1999-04-12
HN1997000040A (es) 1997-06-05
KR100333214B1 (ko) 2002-06-20
AP838A (en) 2000-05-03
CZ289216B6 (cs) 2001-12-12
OA10908A (en) 2001-10-26
AU1936897A (en) 1997-11-26
NZ508303A (en) 2001-07-27
ZA973875B (en) 1998-11-06
YU49398B (sh) 2005-11-28
NO312513B1 (no) 2002-05-21
DE69720719T2 (de) 2003-11-06
US6110918A (en) 2000-08-29
PT904273E (pt) 2003-06-30
IL126590A (en) 2001-11-25
BG102893A (en) 1999-09-30
ES2192264T3 (es) 2003-10-01
CN1216990A (zh) 1999-05-19
AU730856C (en) 2001-11-15
DK0904273T3 (da) 2003-07-07
TNSN97073A1 (fr) 2005-03-15
ME00901B (me) 2005-11-28
SI0904273T1 (en) 2003-08-31
IS4878A (is) 1998-10-23
YU17397A (sh) 2000-10-30
HK1017893A1 (en) 1999-12-03
ID17504A (id) 1998-01-08
UY24543A1 (es) 2000-09-29
BR9708932A (pt) 1999-08-03
ATE236902T1 (de) 2003-04-15
EP0904273B1 (en) 2003-04-09
JPH11509865A (ja) 1999-08-31
SK282674B6 (sk) 2002-11-06
PL188164B1 (pl) 2004-12-31
DZ2221A1 (fr) 2002-12-03
CA2252895C (en) 2002-08-20
EA001180B1 (ru) 2000-10-30
CA2252895A1 (en) 1997-11-13
MY128051A (en) 2007-01-31
CO4940465A1 (es) 2000-07-24
DE69720719D1 (de) 2003-05-15
NO985193D0 (no) 1998-11-06
AR007003A1 (es) 1999-10-13
TR199802241T2 (hu) 1999-02-22
BG63601B1 (bg) 2002-06-28
KR20000010822A (ko) 2000-02-25
JP3102896B2 (ja) 2000-10-23

Similar Documents

Publication Publication Date Title
HUP9902808A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása
HK1017892A1 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
IL106777A (en) Monohydrate of 5-(2-(4-(1, 2-benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6- chloro-1, 3-dihydro-2h- indole-2-one hydrochloride and pharmaceutical compositions comprising it
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
ATE254600T1 (de) Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on
HUP9902404A3 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-choloro-1,3-dihydro-2(2h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist